ribosomal S6 kinase-alpha inhibitors (Boehringer Ingelheim)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameribosomal S6 kinase-alpha inhibitors (Boehringer Ingelheim)
Drug Alias Nameribosomal S6 Kinase inhibitors (Boehringer)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRibosomal protein S6 kinase inhibitors
TargetsRibosomal protein S6 kinase
Therapy Area/IndicationsHeart Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoehringer Ingelheim Corp
Active IndicationsN/A
Inactive IndicationsHeart Failure

Other Information

ATC CodeN/A
Related LinksN/A